by Madaline Spencer | Sep 21, 2026
Marina Kremyanskaya, MD, PhD, Associate Professor at Icahn School of Medicine at Mount Sinai, discusses the phase 2 topline findings from the SANRECO clinical trial and the evolving polycythemia vera (PV) treatment landscape. PV is a condition...
by Madaline Spencer | Sep 19, 2026
The US Food and Drug Administration (FDA) has approved Fayuvi (rebisufligene etisparvovec-hopf; UX111) for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA; Sanfilippo syndrome type A). MPS IIIA is a genetic neurodegenerative disorder...
by Madaline Spencer | Sep 18, 2026
The US Food and Drug Administration (FDA) has approved Bexlutry (lutetium Lu 177 dotatate) injection for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bexlutry is a generic version of Novartis’...
by Madaline Spencer | Sep 17, 2026
Carol Roberts, President of The PBCers Organization, discusses results from the Voice of PBC patient survey. PBC is a chronic, progressive autoimmune liver disease in which the bile ducts become inflamed and damaged. This leads to the buildup of bile...
by Madaline Spencer | Sep 16, 2026
Karen A. Jones, EdD, President and CEO of wAIHA Warriors, discusses the approval of Imaavy (nipocalimab) and its impact on patients with warm autoimmune hemolytic anemia (wAIHA). wAIHA is a rare hematologic autoimmune condition characterized by...
